Equity (Tables)

12 Months Ended

Dec. 31, 2017

Stockholders' Equity Note [Abstract]

Schedule of Warrants and Share Options

	Year ended December 31
	2017					2016
	Number of warrants and options			Weighted average exercise  price		Number of warrants and options			Weighted average exercise price
Outstanding - beginning of period		9,655		$	891.8		864		$	26,337.5
Granted		118			32.2		9,392			159.95
Forfeited		(1,606	)		414.05		(596	)		24,131.45
Exercised		-					(5	)		-
Outstanding -end of period		8,167		$	970.55		9,655		$	891.8
Exercisable at the end of the period		5,295		$	1,431.85		1,465		$	5,087.25

	Year ended December 31
	2017				2016
	Number of warrants and options		Weighted average exercise price		Number of warrants and options			Weighted average exercise price
Outstanding - beginning of period		61		$31,164.7		155		$	39,690
Granted		-		-		-			-
Forfeited		(12)		58,165.8		(107	)		44,749.25
Exercised		-		-		(5	)		-
Outstanding - end of period		49		$21,238.7		43		$	31,164.7
Exercisable at the end of the period		31		$20,874.35		43		$	31,019.8

Schedule of Information About Restricted Shares to Employees

	Year ended December 31
	2017			2016
	Number of restricted shares
Outstanding - beginning of period		3,755			197
Granted		84			3,710
Forfeited		(202	)		(37	)
Vested		(2,544	)		(115	)
Outstanding - end of period		1,093			3,755

Schedule of Warrants and Options Outstanding and Exercisable

	Outstanding as of December 31, 2017
Exercise  price	Options outstanding		Weighted average remaining contractual life (years)		Options exercisable
$0-$65.1		1,483		8.8		850
$106.4-$113.75		3,452		8.69		1,532
$166.25-$288.75		3,049		8.56		2,714
$1,487.5-$7,262.5		98		6.43		96
$19,512.5-$73,500		134		3.26		134
		8,216		8.54		5,326

Schedule of Assumptions Used in Fair Value of Options Granted to Employees

	Year ended December 31
	2017			2016
Expected life	5-6.5 years			5-6.5 years
Risk-free interest rates		1.78%-2.18%			1.01%-2.06%
Volatility		94.42%-97.62%			85.8%-91.03%
Dividend yield		0	%		0	%

Schedule of Allocation of Total Share-based Compensation Expense

	Year ended December 31
	2017		2016
	($ in thousands)
Cost of revenues	$	7	$	1
Research and development		32		182
Sales and marketing		86		(85
General and administrative		547		880
	$	672	$	978